Sugi Predict

Sugi Predict / Compounds / SCHEMBL146434

SCHEMBL146434

SCHEMBL146434

CC([O])C(=O)NCc1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.65
▸ MEN1 O00255 3/20 0.64
▸ ALDH1A1 P00352 2/20 0.64
▸ MAPT P10636 2/20 0.64
▸ MME P08473 1/20 0.59
▸ SLC1A2 P43004 1/20 0.58
▸ CYP3A4 P08684 1/20 0.58
▸ L3MBTL1 Q9Y468 2/20 0.56
▸ MMP8 P22894 1/20 0.56
▸ CA12 O43570 1/20 0.54
▸ CA1 P00915 1/20 0.54
▸ CA2 P00918 1/20 0.54
▸ CA3 P07451 1/20 0.54
▸ CA4 P22748 1/20 0.54
▸ CA6 P23280 1/20 0.54
▸ CA5A P35218 1/20 0.54
▸ CA7 P43166 1/20 0.54
▸ CACNA1C Q13936 1/20 0.54
▸ SCN9A Q15858 1/20 0.54
▸ CA9 Q16790 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2935009 0.87 KMT2A (0.63) KMT2AMEN1ALDH1A1MAPTMME
SCHEMBL8760 0.86 KMT2A (0.67) KMT2AMEN1ALDH1A1MAPTMME
SCHEMBL10405578 0.85 KMT2A (0.65) KMT2AMEN1ALDH1A1MAPTMME
SCHEMBL9062437 0.85 KMT2A (0.65) KMT2AMEN1ALDH1A1MAPTMME
Hydrochloric Acid SCHEMBL23235729 0.85 KMT2A (0.65) KMT2AMEN1ALDH1A1MAPTMME
SCHEMBL23879676 0.84 MME (0.63) KMT2AMEN1ALDH1A1MAPTMME
SCHEMBL7330778 0.83 KMT2A (0.63) KMT2AMEN1ALDH1A1MAPTMME
SCHEMBL5023170 0.83 KMT2A (0.73) KMT2AMEN1ALDH1A1MAPTMME
SCHEMBL21538610 0.83 KMT2A (0.63) KMT2AMEN1ALDH1A1MAPTMME
SCHEMBL21538582 0.83 KMT2A (0.63) KMT2AMEN1ALDH1A1MAPTMME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421533-B1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP (CA) 2018-10-17 — — EP claimed
US-9757368-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2017-09-12 — — US claimed
US-20130281398-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 — — US claimed
US-20120059002-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2012-03-08 — — US claimed
EP-2421533-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2012-02-29 — — EP claimed
WO-2010123975-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2010-10-28 — — WO claimed
CN-107252429-B Novel anti-inflammatory agent 雷斯韦洛吉克斯公司 2023-06-16 — — CN disclosed
EP-3431086-B1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP (CA) 2020-06-17 — — EP disclosed
US-20200129512-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2020-04-30 — — US disclosed
EP-3431086-A1 NOVEL ANTI-INFLAMMATORY AGENTS Resverlogix Corp. (CA) 2019-01-23 — — EP disclosed
EP-2421533-B1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP (CA) 2018-10-17 — — EP disclosed
US-20170333419-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2017-11-23 — — US disclosed
US-20170326143-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2017-11-16 — — US disclosed
US-20120059002-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2012-03-08 — — US disclosed
EP-2421533-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2012-02-29 — — EP disclosed
WO-2010123975-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2010-10-28 — — WO disclosed
US-20070032522-A1 Antiviral agents VIROBAY, INC. 2007-02-08 — — US disclosed
WO-2007005779-A2 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-01-11 — — WO disclosed
EP-1412349-A2 PIPERAZINE OXYQUINOLINE (NAPHTHALINE) PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS Schering Aktiengesellschaft (DE) 2004-04-28 — — EP disclosed
WO-2002098856-A2 PIPERAZINE OXYQUINOLINE (NAPHTHALINE) PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS SCHERING AKTIENGESELLSCHAFT (DE) 2002-12-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059002-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 KMT2A 3505/4885MEN1 1990/4885ALDH1A1 1042/4885
US-20130281398-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION PHKB, BAZ2A, EP300 KMT2A 199/4885MEN1 4236/4885ALDH1A1 3920/4885
US-20170326143-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 KMT2A 3505/4885MEN1 1990/4885ALDH1A1 1042/4885
US-20070032522-A1 Antiviral agents MAVS, HAVCR2, EIF2AK2 KMT2A 4244/4885MEN1 4715/4885ALDH1A1 1481/4885
US-20170333419-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 KMT2A 3505/4885MEN1 1990/4885ALDH1A1 1042/4885
US-20200129512-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 KMT2A 3505/4885MEN1 1990/4885ALDH1A1 1042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.